CoChat

Effect of Ursodeoxycholic Acid Use on the Risk of Colorectal Neoplasia in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Ursodeoxycholic acid (UDCA) may modify the risk of inflammatory bowel disease (IBD)-associated colorectal cancer. We performed a systematic review and meta-analysis of studies evaluating the effect of UDCA on the risk of IBD-associated colorectal neoplasia (CRN) (defined as colorectal cancer and/or dysplasia) in patients with primary sclerosing cholangitis with concomitant IBD (PSC-IBD). METHODS: We conducted a systematic search of Medline, Embase, and Web of Science and manually reviewed the literature. Studies were included if they: (1) evaluated exposure to UDCA in patients with PSC-IBD, (2) reported IBD-associated CRN as outcome, and (3) reported relative risks or odds ratios (ORs) or provided data for their calculation. Summary OR estimates with 95% confidence intervals (CIs) were calculated using the random-effects model. RESULTS: Eight studies (5 observational, 3 randomized controlled trials) reporting 177 cases of CRN in 763 patients with PSC-IBD were included in the analysis. Overall, meta-analysis showed no significant protective association between UDCA use and CRN (OR, 0.81; 95% CI, 0.41-1.61). However, there was a significant chemopreventive effect on the risk of advanced CRN (colorectal cancer and/or high-grade dysplasia) (OR, 0.35; 95% CI, 0.17-0.73). In a subgroup analysis, low-dose UDCA use (8-15 mg/kg/d) was associated with significant risk reduction of CRN (OR, 0.19; 95% CI, 0.08-0.49). CONCLUSIONS: UDCA, particularly at low doses, may reduce the risk of advanced CRN in patients with PSC-IBD. However, results should be interpreted with caution, given limited reporting of cancer-related outcomes, primarily from tertiary care centers.

Overview

Integrity signals

Registry

Crossref · 10.1097/mib.0b013e318286fa61

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Cited by

See all 94

Metadata

Authors
Singh, S., Khanna, S., Pardi, D. S., Loftus, E. V., & Talwalkar, J. A.
Affiliations
Mayo Clinic (US)
Corresponding author
Talwalkar, Jayant A.
Venue
Inflammatory Bowel Diseases
Published
2013-07
Volume
19
Issue
8
Pages
1631-1638
ISSN
1078-0998 (ISSN-L)
OpenAlex
W2316014275
Cited by
94
References
56
Citations by year
2026: 4 · 2025: 13 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 4 · 2019: 9 · 2018: 7 · 2017: 11 · 2016: 7 · 2015: 9 · 2014: 6 · 2013: 3
FWCI
5.19
Type
journal article
Language
en
Open access
closed
Locations
  • Inflammatory Bowel Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
Keywords
ursodeoxycholic acid, primary sclerosing cholangitis
MeSH terms
Cholagogues and Choleretics, Humans, Prognosis, Ursodeoxycholic Acid, Colorectal Neoplasms, Meta-Analysis as Topic, Cholangitis, Sclerosing, Inflammatory Bowel Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Ursodeoxycholic Acid Use on the Risk of Colorectal Neoplasia in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1097/mib.0b013e318286fa61
The paper
Singh, S., Khanna, S., Pardi, D. S., Loftus, E. V., & Talwalkar, J. A. (2013). Effect of Ursodeoxycholic Acid Use on the Risk of Colorectal Neoplasia in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0b013e318286fa61

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.